Sundry Photography/iStock Editorial via Getty Images Boston Scientific (BSX) disclosed that it withdrew and will refile its HSR notification for its planned purchase of Silk Road Medical (NASDAQ:SILK). The filing was withdrawn on Friday and will be refiled on Aug. 13, Silk Road (SILK) said in an 8-K filing on Friday. A new-30 day waiting period under the HSR ACT will expire Sept. 12. The disclosure comes after a note on Thursday indicated that the Silk Road (SILK) deal may potentially see a second request from the Federal Trade Commission. Companies typically pull and refile their HSR notification to try to avoid a second request. The companies overlap in the treatment of carotid artery disease may cause the regulator to seek a more in-depth review, according to traders, who cited a Washington Analysis report on Thursday. Boston Scientific in June announced a deal to acquire medical device company Silk Road Medical (SILK) for $27.50 a share, representing an enterprise value of approximately $1.16B.